

# Natasha M Kafai

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3887256/natasha-m-kafai-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23  
papers

2,074  
citations

11  
h-index

25  
g-index

25  
ext. papers

3,110  
ext. citations

29.5  
avg, IF

4.74  
L-index

#	Paper	IF	Citations
23	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , <b>2022</b> , 14,	17.5	8
22	Distinct Cellular Tropism and Immune Responses to Alphavirus Infection.. <i>Annual Review of Immunology</i> , <b>2022</b> ,	34.7	1
21	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabn1252	17.5	3
20	Structure of Venezuelan equine encephalitis virus in complex with the LDLRAD3 receptor. <i>Nature</i> , <b>2021</b> , 598, 672-676	50.4	1
19	Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice <b>2021</b> ,		1
18	Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	9
17	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , <b>2021</b> , 184, 2183-2200.e22	56.2	145
16	Multivalent designed proteins protect against SARS-CoV-2 variants of concern <b>2021</b> ,		4
15	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. <i>Cell Host and Microbe</i> , <b>2021</b> , 29, 1151-1161.e5	23.4	11
14	Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope. <i>Cell</i> , <b>2021</b> , 184, 4414-4429.e19	56.2	7
13	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains <b>2021</b> ,		11
12	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , <b>2021</b> , eabm3302	17.5	10
11	A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. <i>Cell</i> , <b>2020</b> , 182, 744-753.e4	56.2	337
10	A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Journal of Immunology</i> , <b>2020</b> , 205, 915-922	5.3	126
9	Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis <b>2020</b> ,		9
8	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. <i>Cell</i> , <b>2020</b> , 183, 169-184.e13	56.2	221
7	LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. <i>Nature</i> , <b>2020</b> , 588, 308-314	50.4	22

6	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. <i>Cell Host and Microbe</i> , <b>2020</b> , 28, 465-474.e4	23.4	106
5	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , <b>2020</b> , 584, 443-449	50.4	609
4	SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. <i>Nature Immunology</i> , <b>2020</b> , 21, 1327-1335	19.1	389
3	Malaria in Children. <i>Infectious Disease Clinics of North America</i> , <b>2018</b> , 32, 189-200	6.5	8
2	Suppression of Drug Resistance Reveals a Genetic Mechanism of Metabolic Plasticity in Malaria Parasites. <i>MBio</i> , <b>2018</b> , 9,	7.8	10
1	A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection		5